Furthermore, the incidence of grade 3 or higher TRAEs was 25.6% among those who received dato-DXd vs 42.1% in patients who received paclitaxel in TROPION-Lung01
Practical Guidance (Interim) Clinicians should counsel that current evidence does not justify routine therapeutic use outside registered ethically approved research protocols and that online sourcing introduces quality, legal and professional risk
Back to Journals Journal of Hepatocellular Carcinoma Volume 12 Natural Bioactive Compounds Targeting the Wnt/-Catenin Pathway for the Treatment of Hepatocellular Carcinoma Authors Tian H, Wang P, Shao H Received 19 February 2025 Accepted for publication 11 July 2025 Published 23 July 2025 Volume 2025:12 Pages 16131622 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Ali Hosni Haoyu Tian, Peng Wang, Haibo Shao Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, Liaoning, Peoples Republic of China Correspondence: Haibo Shao, Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, Peoples Republic of China, Email [email protected] Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with limited treatment options and poor prognosis
10.3389/fpubh.2017.00335 82 JiL.-L.ShengY.-C.ZhengZ.-Y.ShiL.WangZ.-T
